Novakand Pharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Selling, General & Admin	6.05	6.22	8.09	7.08	4.33	Upgrade
Research & Development	23.56	39.95	57.99	45.61	42.63	Upgrade
Other Operating Expenses	-0.01	-0.01	-	-	-0	Upgrade
Operating Expenses	29.59	46.16	66.08	52.69	46.96	Upgrade
Operating Income	-29.59	-46.16	-66.08	-52.69	-46.96	Upgrade
Interest Expense	-	-	-	-0.12	-0.02	Upgrade
Interest & Investment Income	0.37	1.6	0.28	0.07	-	Upgrade
Currency Exchange Gain (Loss)	-	-	0.45	-0.09	-0.25	Upgrade
Other Non Operating Income (Expenses)	-	-	0.46	0.34	1.54	Upgrade
EBT Excluding Unusual Items	-29.23	-44.57	-64.89	-52.48	-45.69	Upgrade
Asset Writedown	-18	-	-	-	-	Upgrade
Pretax Income	-47.23	-44.57	-64.89	-52.48	-45.69	Upgrade
Net Income	-47.23	-44.57	-64.89	-52.48	-45.69	Upgrade
Net Income to Common	-47.23	-44.57	-64.89	-52.48	-45.69	Upgrade
Shares Outstanding (Basic)	121	115	80	58	56	Upgrade
Shares Outstanding (Diluted)	121	115	80	58	56	Upgrade
Shares Change (YoY)	5.08%	44.85%	36.90%	3.91%	54.18%	Upgrade
EPS (Basic)	-0.39	-0.39	-0.81	-0.90	-0.82	Upgrade
EPS (Diluted)	-0.39	-0.39	-0.81	-0.90	-0.82	Upgrade
Free Cash Flow	-30.29	-58.53	-55.67	-47.56	-44.13	Upgrade
Free Cash Flow Per Share	-0.25	-0.51	-0.70	-0.82	-0.79	Upgrade
EBITDA	-	-43.16	-63.08	-52.33	-46.64	Upgrade
D&A For EBITDA	-	3	3	0.36	0.32	Upgrade
EBIT	-29.59	-46.16	-66.08	-52.69	-46.96	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.